# Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known

> **NCT01971476** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 22 (actual)

## Conditions studied

- Leukemia
- Neoplasms

## Interventions

- **DRUG:** volasertib

## Key facts

- **NCT ID:** NCT01971476
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-22
- **Primary completion:** 2015-06-01
- **Final completion:** 2017-01-27
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2018-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01971476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01971476, "Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01971476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*